The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and long treatment durations. The availability of premium-priced branded agents prescribed in multidrug regimens, particularly Darzalex-based therapies, is impacting the disease’s treatment algorithm. Although Revlimid and bortezomib remain the cornerstones of treatment, recently approved therapies (GlaxoSmithKline’s Blenrep, Sanofi’s Sarclisa, and Bristol Myers Squibb / Bluebird Bio’s Abecma) have expanded the number of options available. The anti-BCMA bispecific agents (e.g., Pfizer’s elranatamab and Janssen’s teclistamab) in addition to the CAR T-cell therapies (e.g., Janssen’s ciltacabtagene autoleucel) are also expected to compete fiercely, along with AbbVie / Roche’s Venclexta / Venclyxto. Nevertheless, clinical and commercial potential exists for multiple myeloma therapies with improved efficacy, a novel mechanism of action, and/or the ability to treat underserved patient segments, such as smoldering multiple myeloma.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continuous updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 32 country-specific interviews with experts and country-specific surveys with 210 hematologist-oncologists treating multiple myeloma.
Epidemiology: Incidence of multiple myeloma by country, segmented by symptom.
Emerging therapies: Phase III/PR: 4 drugs; coverage of select Phase I and II products.